Patents by Inventor Torben Gjetting

Torben Gjetting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20240052032
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, such as cancer.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 15, 2024
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-lag-3 antibodies and compositions
    Patent number: 11834503
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: December 5, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-AXL antibodies and compositions
    Patent number: 11807688
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 7, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
  • ANTI-CD73 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230227573
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 20, 2023
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • Anti-CD73 antibodies and compositions
    Patent number: 11634500
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 25, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad Grandal, Torben Gjetting, Johan Lantto, Janus Schou Jakobsen, Randi Westh Hansen, Camilla Fröhlich
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230105714
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220363757
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: November 17, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-TIM-3 antibodies and compositions
    Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-LAG-3 antibodies and compositions
    Patent number: 11390676
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-PD-1 antibodies and compositions
    Patent number: 11359018
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 14, 2022
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Thomas Bouquin, Klaus Koefoed, Torben Gjetting, Vikram Kjoller Bhatia, Monika Gad, Gunther Roland Galler, Camilla Frohlich
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220056126
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 24, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-AXL Antibodies and Compositions
    Publication number: 20210269532
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Torben GJETTING, Trine LINDSTED, Anton WILLER, Anne WORSAAE, Maria Carlsen MELANDER, Janus Schou JAKOBSEN, Randi Westh HANSEN
  • ANTI-CD73 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210070876
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • Anti-PD-1 Antibodies and Compositions
    Publication number: 20190367616
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Johan LANTTO, Thomas BOUQUIN, Klaus KOEFOED, Torben GJETTING, Vikram Kjoller BHATIA, Monika GAD, Gunther Roland GALLER, Camilla FROHLICH
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Charge triggering of self-organized nanoparticles
    Patent number: 9161993
    Abstract: The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least ?2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least ?1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 20, 2015
    Assignee: Danmarks Tekniske Universitet
    Inventors: Rasmus Irming Jølck, Jonas Rosager Henriksen, Torben Gjetting, Thomas Lars Andresen
  • CHARGE TRIGGERING OF SELF-ORGANIZED NANOPARTICLES
    Publication number: 20140328897
    Abstract: The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least ?2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least ?1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 6, 2014
    Applicant: DANMARKS TEKNISKE UNIVERSITET
    Inventors: Rasmus Irming Jølck, Jonas Rosager Henriksen, Torben Gjetting, Thomas Lars Andresen